Delirium Market Outlook | Size, Drugs, Epidemiology Trends and Forecast to 2035

What is delirium?

A delirium is a severe, acute change in mental status, characterised by disorganized thinking and reduced awareness of one's environment; delirium typically takes on an abrupt onset, usually in hours or days, and tends to be transient and reversible. There are three primary forms of delirium: hyperactive delirium, where the patient may be restless, agitated, or exhibit rapid shifts in mood; hypoactive delirium, where patients become lethargic, drowsy, or withdrawn; and mixed delirium, which is a fluctuation between both the hyperactive and hypoactive forms. Surprisingly, hypoactive delirium is rapidly gaining recognition for its emergent requirement for appropriate treatment, largely due to its often subtle presentation.

The development of delirium has multiple underlying medical causes. Some of the most common causes are advanced cancer, alcohol or drug intoxication or withdrawal, dehydration, electrolyte disorders, existing dementia, hospitalization, especially intensive care unit hospitalization, infection (e.g., urinary tract infection or pneumonia), side effects or withdrawal from specific medications, metabolic disturbances, organ failure, pain, and sleep deprivation. Significant contributors prominently increasing one's risk of developing delirium include advanced age, history of dementia, severe or multiple chronic illnesses, and recent surgery.

The delirium market reached a value of USD 194.4 Million in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 299.9 Million by 2035, exhibiting a growth rate (CAGR) of 4.04% during 2025-2035. This consistent increase also highlights the increasing importance and investment in addressing this complex medical syndrome. Increasing awareness of hypoactive delirium as a significant proportion significantly contributes to this market increase.

Hypoactive delirium, often less externally overt than hyperactive delirium, has been underdiagnosed in the past as well. Its growing visibility in market share is a testament to a concerted effort throughout healthcare to identify and treat this stealthy variant, associated with equally, if not more, severe consequences. This improved diagnostic capability directly fuels demand for skilled products and interventions and is a marker of clinical maturity and practice in delirium management. This movement indicates that healthcare systems are going towards a more holistic and sophisticated way of assessing patients in order to catch all types of delirium, hence enhancing overall patient safety and outcomes.

Improvements in Delirium Detection and Diagnosis

Traditional Diagnostic Methods

Historically relied on:

• Extensive medical history
• Physical and neurological examinations
• Mental status evaluations to assess cognitive functions and alertness

Adoption of Standardized Assessment Instruments

Universal implementation of structured tools is revolutionizing delirium diagnosis.

Commonly used instruments:

• Confusion Assessment Method (CAM)
• Delirium Observation Screening Scale (DOS)

Benefits:

• Enables a wider range of healthcare providers, including non-specialists, to identify and diagnose delirium
• Promotes timely intervention and improved patient care outcome

Integration of Artificial Intelligence and Machine Learning

AI and ML algorithms provide objective and efficient diagnostic strategies.

Combined use with portable EEG technology enhances:

• Diagnostic accuracy
• Rapid bedside identification of delirium
• Facilitates faster, data-driven decision-making in clinical settings

Advances in Biomarker Research

• Focused on molecular-level detection of delirium
• Benefits of biomarker-based detection:
• Early and precise identification
• Better clinical decision-making guidance
• Potential to detect risk before symptoms appear

Shift Towards Predictive and Preventive Medicine

AI, ML, and biomarkers enable predictive analytics for:

• Identifying high-risk patients **before symptom onset**
• Implementing **individualized preventative measures
• Moves delirium care from reactive symptom control to proactive prevention

Impact on Healthcare Outcomes and Costs

Potential benefits include:

• Reduced delirium severity
• Shorter hospital stays
• Lower risk of complications
• Decreased long-term care needs

This delirium market report also provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Competitive Landscape With Key Players:

The competitive landscape of the delirium market has been studied in the report with the detailed profiles of the key players operating in the market.

Request for a Sample Copy of this Report: https://www.imarcgroup.com/delirium-market/requestsample

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

Company Name: IMARC Group

Email: [email protected]

Phone: +1-201-971-6302

Address: 134 N 4th St

City: Brooklyn

State: NY

Country: United States

Website: https://www.imarcgroup.com/